Tag Archives: AstraZeneca

Concepts for Consideration

 (from NeuroPerspective July-August 2014) 1) Biometheus and the Placebo Response Gene: Biometheus has licensed IP related to a COMT gene polymorphism that they believe identifies patients prone to placebo-response.  As they discussed in BioCentury, the developers have published work showing … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , , , , , | 1 Comment